May 3 (Reuters) - Canada’s Valeant Pharmaceuticals International Inc reported a quarterly loss hurt in part by higher costs.
The company also said it would buy a few assets of University Medical Pharmaceuticals Corp, which is focused on skincare products, for about $64 million plus potential milestones.
The transaction is expected to close by the middle of the year.
First-quarter net loss was $12.9 million, or 4 cents per share, compared with a net income of $6.5 million, or 2 cents per share, a year earlier.
Revenue rose 52 percent to $856 million.